Discovery of biomarkers for gastric cancer: A proteomics approach

Journal of Proteomics

Volumn 75, Issue 11, 2012, Pages 3081-3097

  Lin, Li Ling ^a   Huang, Hsuan Cheng ^b   Juan, Hsueh Fen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Gastric cancer; Mass spectrometry; Proteomics

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; CA 19-9 ANTIGEN; CATHEPSIN B; CISPLATIN; DAUNORUBICIN; DIALLYL TRISULFIDE; DOXORUBICIN; GALECTIN 2; LACTATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; RETINOIC ACID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLOOD; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELLS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH JUICE; TISSUES;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

HELICOBACTER PYLORI;

EID: 84861706473     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.046     Document Type: Review

References (131)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, [Internet]. Available: http://globocan.iarc.fr.
3. Mirvish S.S. Gastric cancer and salivary nitrate and nitrite. Nature 1985, 315:461-462.
4. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991, 325:1127-1131.
5. Lo S.S., Wu C.W., Hsieh M.C., Kuo H.S., Lui W.Y., P'Eng F.K. Relationship between age and clinical characteristics of patients with gastric cancer. J Gastroenterol Hepatol 1996, 11:511-514.
6. Hwang H., Dwyer J., Russell R.M. Diet, Helicobacter pylori infection, food preservation and gastric cancer risk: are there new roles for preventative factors?. Nutr Rev 1994, 52:75-83.
7. Ushijima T., Sasako M. Focus on gastric cancer. Cancer Cell 2004, 5:121-125.
8. Ohta H., Noguchi Y., Takagi K., Nishi Y., Kajitani T., Kati Y. Early gastric carcinoma with special reference to macroscopic classification. Cancer 1987, 60:1099-1106.
9. Peddanna N., Holt S., Verma R.S. Genetics of gastric cancer. Anticancer Res 1995, 15:2055-2064.
10. Yanagawa T., Hayashi Y., Nishida T., Yoshida H., Yura Y., Azuma M., et al. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) on tissue sections from squamous cell head and neck cancer and plasma CEA levels of the patients. Int J Oral Maxillofac Surg 1986, 15:296-306.
11. Johnson P.J., Leung N., Cheng P., Welby C., Leung W.T., Lau W.Y., et al. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997, 75:236-240.
12. Bast R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309:883-887.
13. Fletcher R.H. Carcinoembryonic antigen. Ann Intern Med 1986, 104:66-73.
14. Satake K., Takeuchi T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994, 9:720-724.
15. Caplan A., Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002, 117(Suppl.):S104-S108.
16. Ebert M.P., Rocken C. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 2006, 18:847-853.
17. Nardone G. Review article: molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther 2003, 17(Suppl. 2):75-81.
18. Tjalsma H., Bolhuis A., Jongbloed J.D., Bron S., van Dijl J.M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 2000, 64:515-547.
19. Liu W., Liu B., Xin L., Zhang Y., Chen X., Zhu Z., et al. Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin Chim Acta 2007, 377:119-126.
20. Chong P.K., Lee H., Loh M.C., Choong L.Y., Lin Q., So J.B., et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10:3210-3221.
21. Hao Y., Yu Y., Wang L., Yan M., Ji J., Qu Y., et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 2008, 7:3668-3677.
22. Tsunemi S., Nakanishi T., Fujita Y., Bouras G., Miyamoto Y., Miyamoto A., et al. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep 2010, 23:949-956.
23. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010, 9:3671-3679.
24. Juan H.F., Chen J.H., Hsu W.T., Huang S.C., Chen S.T., Yi-Chung Lin J., et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4:2766-2775.
25. Ebert M.P., Meuer J., Wiemer J.C., Schulz H.U., Reymond M.A., Traugott U., et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 2004, 3:1261-1266.
26. Su Y., Shen J., Qian H., Ma H., Ji J., Ma L., et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007, 98:37-43.
27. Miyagi Y., Higashiyama M., Gochi A., Akaike M., Ishikawa T., Miura T., et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011, 6:e24143.
28. Bones J., Byrne J.C., O'Donoghue N., McManus C., Scaife C., Boissin H., et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011, 10:1246-1265.
29. Cohen M., Yossef R., Erez T., Kugel A., Welt M., Karpasas M.M., et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One 2011, 6:e14540.
30. Ebert M.P., Niemeyer D., Deininger S.O., Wex T., Knippig C., Hoffmann J., et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res 2006, 5:2152-2158.
31. Ebert M.P., Lamer S., Meuer J., Malfertheiner P., Reymond M., Buschmann T., et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 2005, 4:586-590.
32. Xia H.H., Yang Y., Chu K.M., Gu Q., Zhang Y.Y., He H., et al. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 2009, 115:5441-5449.
33. Umemura H., Togawa A., Sogawa K., Satoh M., Mogushi K., Nishimura M., et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol 2011, 46:577-585.
34. Farrar G.E., Bower R.J. Gastric juice and secretion: physiology and variations in disease. Annu Rev Physiol 1967, 29:141-168.
35. Kon O.L., Yip T.T., Ho M.F., Chan W.H., Wong W.K., Tan S.Y., et al. The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics 2008, 1:54.
36. Hsu P.I., Chen C.H., Hsieh C.S., Chang W.C., Lai K.H., Lo G.H., et al. Alpha1-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer. Clin Cancer Res 2007, 13:876-883.
37. Kam S.Y., Hennessy T., Chua S.C., Gan C.S., Philp R., Hon K.K., et al. Characterization of the human gastric fluid proteome reveals distinct pH-dependent protein profiles: implications for biomarker studies. J Proteome Res 2011, 10:4535-4546.
38. Xia Y.J., Ma Y.Y., He X.J., Wang H.J., Ye Z.Y., Tao H.Q. Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. Hum Pathol 2011, 42:1620-1628.
39. Bai Z., Ye Y., Liang B., Xu F., Zhang H., Zhang Y., et al. Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. Int J Oncol 2011, 38:375-383.
40. Balluff B., Rauser S., Meding S., Elsner M., Schone C., Feuchtinger A., et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011, 179:2720-2729.
41. He Q.Y., Cheung Y.H., Leung S.Y., Yuen S.T., Chu K.M., Chiu J.F. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004, 4:3276-3287.
42. Chen J., Kahne T., Rocken C., Gotze T., Yu J., Sung J.J., et al. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 2004, 3:1009-1016.
43. Kikuta K., Kubota D., Saito T., Orita H., Yoashida A., Tsuda H., et al. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients gastrointestinal stromal tumor. J Proteomics 2012, 75:1089-1098.
44. Jia S.Q., Niu Z.J., Zhang L.H., Zhong X.Y., Shi T., Du H., et al. Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics. J Cancer Res Clin Oncol 2009, 135:403-411.
45. Melle C., Ernst G., Schimmel B., Bleul A., Kaufmann R., Hommann M., et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res 2005, 4:1799-1804.
46. Kim H.K., Reyzer M.L., Choi I.J., Kim C.G., Kim H.S., Oshima A., et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010, 9:4123-4130.
47. Liu R., Li Z., Bai S., Zhang H., Tang M., Lei Y., et al. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics 2009, 8:70-85.
48. Cai Z., Zhao J.S., Li J.J., Peng D.N., Wang X.Y., Chen T.L., et al. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics 2010, 9:2617-2628.
49. Jung J.H., Kim H.J., Yeom J., Yoo C., Shin J., Yoo J., et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol 2012, 47:37-48.
50. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., So J.B., et al. Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model. J Proteomics 2010, 73:1632-1640.
51. Balluff B., Elsner M., Kowarsch A., Rauser S., Meding S., Schuhmacher C., et al. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res 2010, 9:6317-6322.
52. Mohri Y., Mohri T., Wei W., Qi Y.J., Martin A., Miki C., et al. Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer 2009, 101:295-302.
53. Dohi T., Ohta S., Hanai N., Yamaguchi K., Oshima M. Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosa. J Biol Chem 1990, 265:7880-7885.
54. Chen C.D., Wang C.S., Huang Y.H., Chien K.Y., Liang Y., Chen W.J., et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics 2007, 7:155-167.
55. Chen Y.R., Juan H.F., Huang H.C., Huang H.H., Lee Y.J., Liao M.Y., et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 2006, 5:2727-2742.
56. Momynaliev K.T., Kashin S.V., Chelysheva V.V., Selezneva O.V., Demina I.A., Serebryakova M.V., et al. Functional divergence of Helicobacter pylori related to early gastric cancer. J Proteome Res 2010, 9:254-267.
57. Fushida S., Yonemura Y., Urano T., Yamaguchi A., Miyazaki I., Nakamura T., et al. Expression of hepatocyte growth factor(hgf) and C-met gene in human gastric-cancer cell-lines. Int J Oncol 1993, 3:1067-1070.
58. Yonemura Y., Kaji M., Hirono Y., Fushida S., Tsugawa K., Fujimura T., et al. Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 1996, 8:555-560.
59. Guo T., Zhu Y., Gan C.S., Lee S.S., Zhu J., Wang H., et al. Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells. Mol Cell Proteomics 2010, 9:2629-2641.
60. Torti D., Sassi F., Galimi F., Gastaldi S., Perera T., Comoglio P.M., et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer 2012, 130:1357-1366.
61. Yan G.R., Xu S.H., Tan Z.L., Yin X.F., He Q.Y. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric cancer cells. Proteomics 2011, 11:3657-3664.
62. Oda Y., Nagasu T., Chait B.T. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 2001, 19:379-382.
63. Guo T., Lee S.S., Ng W.H., Zhu Y., Gan C.S., Zhu J., et al. Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome. Cell Mol Life Sci 2011, 68:1983-2002.
64. Kim H.K., Park W.S., Kang S.H., Warda M., Kim N., Ko J.H., et al. Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol 2007, 293:C761-C771.
65. Peterson W.L. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991, 324:1043-1048.
66. Jungblut P.R., Bumann D., Haas G., Zimny-Arndt U., Holland P., Lamer S., et al. Comparative proteome analysis of Helicobacter pylori. Mol Microbiol 2000, 36:710-725.
67. Krah A., Schmidt F., Becher D., Schmid M., Albrecht D., Rack A., et al. Analysis of automatically generated peptide mass fingerprints of cellular proteins and antigens from Helicobacter pylori 26695 separated by two-dimensional electrophoresis. Mol Cell Proteomics 2003, 2:1271-1283.
68. Sabarth N., Lamer S., Zimny-Arndt U., Jungblut P.R., Meyer T.F., Bumann D. Identification of surface proteins of Helicobacter pylori by selective biotinylation, affinity purification, and two-dimensional gel electrophoresis. J Biol Chem 2002, 277:27896-27902.
69. Bumann D., Aksu S., Wendland M., Janek K., Zimny-Arndt U., Sabarth N., et al. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect Immun 2002, 70:3396-3403.
70. Backert S., Kwok T., Schmid M., Selbach M., Moese S., Peek R.M., et al. Subproteomes of soluble and structure-bound Helicobacter pylori proteins analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1331-1345.
71. Jungblut P.R., Schiele F., Zimny-Arndt U., Ackermann R., Schmid M., Lange S., et al. Helicobacter pylori proteomics by 2-DE/MS, 1-DE-LC/MS and functional data mining. Proteomics 2010, 10:182-193.
72. Bernardini G., Braconi D., Lusini P., Santucci A. Helicobacter pylori: immunoproteomics related to different pathologies. Expert Rev Proteomics 2007, 4:679-689.
73. Lahner E., Bernardini G., Possenti S., Renzone G., Scaloni A., Santucci A., et al. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. Int J Med Microbiol 2011, 301:125-132.
74. Mini R., Bernardini G., Salzano A.M., Renzone G., Scaloni A., Figura N., et al. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 833:63-79.
75. Lin Y.F., Wu M.S., Chang C.C., Lin S.W., Lin J.T., Sun Y.J., et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol Cell Proteomics 2006, 5:1484-1496.
76. Das S., Sierra J.C., Soman K.V., Suarez G., Mohammad A.A., Dang T.A., et al. Differential protein expression profiles of gastric epithelial cells following Helicobacter pylori infection using ProteinChips. J Proteome Res 2005, 4:920-930.
77. Lin L.L., Chen C.N., Lin W.C., Lee P.H., Chang K.J., Lai Y.P., et al. Annexin A4: A novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl 2008, 2:619-634.
78. Backert S., Gressmann H., Kwok T., Zimny-Arndt U., Konig W., Jungblut P.R., et al. Gene expression and protein profiling of AGS gastric epithelial cells upon infection with Helicobacter pylori. Proteomics 2005, 5:3902-3918.
79. Holland C., Schmid M., Zimny-Arndt U., Rohloff J., Stein R., Jungblut P.R., et al. Quantitative phosphoproteomics reveals link between Helicobacter pylori infection and RNA splicing modulation in host cells. Proteomics 2011, 11:2798-2811.
80. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3:243-252.
81. McVicar J.P., Kunitake S.T., Hamilton R.L., Kane J.P. Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. Proc Natl Acad Sci U S A 1984, 81:1356-1360.
82. Sporn L.A., Bunce L.A., Francis C.W. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood 1995, 86:1802-1810.
83. 2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005, 6:449-461.
84. Deng L., Su T., Leng A., Zhang X., Xu M., Yan L., et al. Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol 2010, 27:1102-1108.
85. Datta P.K., Moses H.L. STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol 2000, 20:3157-3167.
86. Zhang J., Kang B., Tan X., Bai Z., Liang Y., Xing R., et al. Comparative analysis of the protein profiles from primary gastric tumors and their adjacent regions: MAWBP could be a new protein candidate involved in gastric cancer. J Proteome Res 2007, 6:4423-4432.
87. Tseng C.W., Yang J.C., Chen C.N., Huang H.C., Chuang K.N., Lin C.C., et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics 2011, 11:2423-2439.
88. Kuramitsu Y., Baron B., Yoshino S., Zhang X., Tanaka T., Yashiro M., et al. Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res 2010, 30:4459-4465.
89. Natoli E.J., Livingston P.O., Pukel C.S., Lloyd K.O., Wiegandt H., Szalay J., et al. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res 1986, 46:4116-4120.
90. Jin D.Y., Spencer F., Jeang K.T. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998, 93:81-91.
91. Iwanaga Y., Kasai T., Kibler K., Jeang K.T. Characterization of regions in hsMAD1 needed for binding hsMAD2. A polymorphic change in an hsMAD1 leucine zipper affects MAD1-MAD2 interaction and spindle checkpoint function. J Biol Chem 2002, 277:31005-31013.
92. Nishigaki R., Osaki M., Hiratsuka M., Toda T., Murakami K., Jeang K.T., et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005, 5:3205-3213.
93. Hino M., Kurogi K., Okubo M.A., Murata-Hori M., Hosoya H. Small heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa cells. Biochem Biophys Res Commun 2000, 271:164-169.
94. Babic A.M., Kireeva M.L., Kolesnikova T.V., Lau L.F. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998, 95:6355-6360.
95. Tong X., O'Kelly J., Xie D., Mori A., Lemp N., McKenna R., et al. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 2004, 23:4847-4855.
96. Derian C.K., Damiano B.P., D'Andrea M.R., Andrade-Gordon P. Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry (Mosc) 2002, 67:56-64.
97. Caygill C.P., Leach S.A., Kirkham J.S., Northfield T.C., Hall C.N., Hill M.J. Gastric hypoacidity as a risk factor for gastric and other cancers. IARC Sci Publ 1987, 524-526.
98. Zhang C., Yamada N., Wu Y.L., Wen M., Matsuhisa T., Matsukura N. Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. World J Gastroenterol 2005, 11:791-796.
99. Liantonio A., Accardi A., Carbonara G., Fracchiolla G., Loiodice F., Tortorella P., et al. Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid. Mol Pharmacol 2002, 62:265-271.
100. Yoo H.H., Chung I.K. Requirement of DDX39 DEAD box RNA helicase for genome integrity and telomere protection. Aging Cell 2011, 10:557-571.
101. Nedjadi T., Kitteringham N., Campbell F., Jenkins R.E., Park B.K., Navarro P., et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer 2009, 101:1145-1154.
102. Slomnicki L.P., Nawrot B., Lesniak W. S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol 2009, 41:784-790.
103. Ebert M.P., Kruger S., Fogeron M.L., Lamer S., Chen J., Pross M., et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005, 5:1693-1704.
104. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997, 94:6658-6663.
105. Pyke C., Romer J., Kallunki P., Lund L.R., Ralfkiaer E., Dano K., et al. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994, 145:782-791.
106. Koshikawa N., Moriyama K., Takamura H., Mizushima H., Nagashima Y., Yanoma S., et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res 1999, 59:5596-5601.
107. Liu Z., Wang X., Lu Y., Han S., Zhang F., Zhai H., et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008, 29:1219-1227.
108. Weigelt B., Peterse J.L., van 't Veer L.J. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
109. Yoon W.H., Song I.S., Lee B.H., Jung Y.J., Kim T.D., Li G., et al. Differential regulation of vimentin mRNA by 12-O-tetradecanoylphorbol 13-acetate and all-trans-retinoic acid correlates with motility of Hep 3B human hepatocellular carcinoma cells. Cancer Lett 2004, 203:99-105.
110. Irie A., Yamauchi A., Kontani K., Kihara M., Liu D., Shirato Y., et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005, 11:2962-2968.
111. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008, 29:22-28.
112. Yang Y., Lim S.K., Choong L.Y., Lee H., Chen Y., Chong P.K., et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 2010, 9:4767-4778.
113. Wrutniak-Cabello C., Casas F., Cabello G. Thyroid hormone action in mitochondria. J Mol Endocrinol 2001, 26:67-77.
114. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000, 60:4693-4696.
115. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999, 17:94-95.
116. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
117. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7:504-516.
118. Yang Y.X., Chen Z.C., Zhang G.Y., Yi H., Xiao Z.Q. A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem 2008, 104:1010-1021.
119. Li N., Guo R., Li W., Shao J., Li S., Zhao K., et al. A proteomic investigation into a human gastric cancer cell line BGC823 treated with diallyl trisulfide. Carcinogenesis 2006, 27:1222-1231.
120. Herman-Antosiewicz A., Singh S.V. Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organosulfur compounds: a review. Mutat Res 2004, 555:121-131.
121. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., Lage H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 1998, 37:105-116.
122. Yang Y.X., Xiao Z.Q., Chen Z.C., Zhang G.Y., Yi H., Zhang P.F., et al. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006, 6:2009-2021.
123. Chung Y.M., Park S., Park J.K., Kim Y., Kang Y., Yoo Y.D. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000, 159:95-101.
124. Vargas-Roig L.M., Gago F.E., Tello O., Aznar J.C., Ciocca D.R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998, 79:468-475.
125. Degos L., Wang Z.Y. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001, 20:7140-7145.
126. Ping S., Wang S., Zhang J., Peng X. Effect of all-trans-retinoic acid on mRNA binding protein p62 in human gastric cancer cells. Int J Biochem Cell Biol 2005, 37:616-627.
127. Wang X., Lu Y., Yang J., Shi Y., Lan M., Liu Z., et al. Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis. J Cancer Res Clin Oncol 2008, 134:995-1003.
128. Yoo B.C., Ku J.L., Hong S.H., Shin Y.K., Park S.Y., Kim H.K., et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004, 108:532-539.
129. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
130. Morikawa T., Kato J., Yamaji Y., Wada R., Mitsushima T., Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
131. Tseng C.W., Lin C.C., Chen C.N., Huang H.C., Juan H.F. Integrative network analysis reveals active microRNAs and their functions in gastric cancer. BMC Syst Biol 2011, 5:99.